Investor Information


Psyence Group Announces SEC Effectiveness Of F-4 For Proposed Business Combination Between Subsidiary And NASDAQ Listed Newcourt Acquisitions Corp

2023-11-15T20:55:16+02:00November 15, 2023|Press Releases, Investor Information|

Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp  (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration statement on Form F-4 (the “Registration Statement”), filed by Psyence Biomedical Ltd. (“Pubco”) with the Securities and Exchange Commission (“SEC”) was declared effective by the SEC on November 13, 2023.

  • Corporate Updates - Psyence

Psyence Group Corporate Update

2023-08-02T14:35:09+02:00July 12, 2023|Press Releases, Investor Information|

Since Psyence’s corporate update issued in June 2022, the Company has made significant progress in its clinical trial programs and in upgrading its production facility and extraction capabilities. Psyence is executing on its strategy and is pleased to provide an update across the pillars of the business.

  • Psyence Corporate Update

Psyence Group Announces Closing Of Fourth Round Tranche Of Private Placement And Conversion Of Convertible Debt Note

2023-04-04T06:53:49+02:00April 4, 2023|Press Releases, Investor Information|

Psyence is pleased to announce that it has issued 9,043,038 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$1,085,164. This brings the total amount the Company has raised pursuant to the previously announced private placement to CAD $3.04 million ("Aggregate Proceeds").

Go to Top